The most frequent adverse event in the nintedanib groups was diarrhea , with rates of 61.5 % and 18.6 % in the nintedanib and placebo groups , respectively , in INPULSIS-1 and 63.2 % and 18.3 % in the two groups , respectively , in INPULSIS-2 .